Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei Jing Loo

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical, Cosmetic and Investigational Dermatology|January 27, 2025
Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian ExperienceElena Tay, Wei Jing Loo
Drugs & Aging|September 24, 2004
Management of autoimmune skin disorders in the elderlyWei Jing Loo, Nigel P Burrows
Journal of Cutaneous Medicine and Surgery|July 21, 2010
Psoriasis and multiple sclerosis: is there a link?Tiffany Kwok, Wei Jing Loo, Lyn Guenther
The Health Service Journal|November 24, 2004
Clinical management where medicine meets management. More than skin deepNigel Burrows, Paul Norris, Wei Jing Loo
Journal of Cutaneous Medicine and Surgery|September 14, 2012
The coexistence of psoriasis and vitiligo: a reviewMichael Sawchuk, Frank Spano, Wei Jing Loo, et al.
Journal of Drugs in Dermatology : JDD|October 11, 2022
Phase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic DermatitisCharles Lynde, Yves Poulin, Jerry Tan, et al.
Dermatology and Therapy|February 19, 2024
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyValerie J Ludbrook, David C Budd, Katie Thorn, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Eclinicalmedicine|February 23, 2023
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyHoward Sofen, Robert Bissonnette, Gil Yosipovitch, et al.
Journal of Cutaneous Medicine and Surgery|March 26, 2026
Disease Burden in a Cohort of Canadian Adults With Moderate-to-Severe Atopic Dermatitis by Systemic Therapy UseMelinda J Gooderham, Maksym Breslavets, Irina Turchin, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical, Cosmetic and Investigational Dermatology|January 27, 2025
Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian ExperienceElena Tay, Wei Jing Loo
Drugs & Aging|September 24, 2004
Management of autoimmune skin disorders in the elderlyWei Jing Loo, Nigel P Burrows
Journal of Cutaneous Medicine and Surgery|July 21, 2010
Psoriasis and multiple sclerosis: is there a link?Tiffany Kwok, Wei Jing Loo, Lyn Guenther
The Health Service Journal|November 24, 2004
Clinical management where medicine meets management. More than skin deepNigel Burrows, Paul Norris, Wei Jing Loo
Journal of Cutaneous Medicine and Surgery|September 14, 2012
The coexistence of psoriasis and vitiligo: a reviewMichael Sawchuk, Frank Spano, Wei Jing Loo, et al.
Journal of Drugs in Dermatology : JDD|October 11, 2022
Phase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic DermatitisCharles Lynde, Yves Poulin, Jerry Tan, et al.
Dermatology and Therapy|February 19, 2024
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyValerie J Ludbrook, David C Budd, Katie Thorn, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Eclinicalmedicine|February 23, 2023
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyHoward Sofen, Robert Bissonnette, Gil Yosipovitch, et al.
Journal of Cutaneous Medicine and Surgery|March 26, 2026
Disease Burden in a Cohort of Canadian Adults With Moderate-to-Severe Atopic Dermatitis by Systemic Therapy UseMelinda J Gooderham, Maksym Breslavets, Irina Turchin, et al.
Pageof 2